- Home
- BWIV vs AARD Comparison
BWIV vs AARD Comparison
Compare BWIV & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWIV | AARD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.0M | 107.7M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BWIV | AARD |
|---|---|---|
| Price | $9.96 | $5.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 44.7K | ★ 122.1K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $3.35 |
| 52 Week High | $10.00 | $17.94 |
Technical Indicators
Market Signals| Indicator | BWIV | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 47.69 |
| Support Level | $9.90 | $5.47 |
| Resistance Level | $10.00 | $6.01 |
| Average True Range (ATR) | 0.01 | 0.54 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 55.56 | 61.72 |
Price Performance
Historical ComparisonAbout BWIV Blue Water Acquisition Corp. IV Class A Ordinary Shares
Blue Water Acquisition Corp IV is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.